Correspondence 0001185185-24-000442 from IGC Pharma, Inc. (IGC)

IGC Pharma, Inc.
Date: April 30, 2024 · CIK: 0001326205 · Accession: 0001185185-24-000442

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-278775

Date

April 30, 2024

Author

Ram Mukunda

Form

CORRESP

Company

IGC Pharma, Inc.

Letter

igcpharma20240430_corresp.htm

April 30, 2024

VIA EMAIL AND EDGAR

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Tim Buchmiller, Esq.

Division of Corporation Finance

Re: IGC Pharma, Inc.

Registration Statement on Form S-3 (No. 333-278775)

Ladies and Gentlemen:

On behalf of IGC Pharma, Inc. (the “Company”), we enclose the Company’s request for acceleration of the above-referenced Registration Statement to 4:00 p.m., Eastern time, on Thursday, May 2, 2024, or as soon as possible thereafter.

Please advise the undersigned of the effectiveness of the Registration Statement.

Very truly yours,

/s/ Kenneth Schlesinger

Kenneth Schlesinger

cc: Mr. Ram Mukunda

Ms. Claudia Grimaldi

IGC Pharma, Inc.

10224 Falls Road

Potomac, MD 20854

April 30, 2024

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Tim Buchmiller, Esq.

Division of Corporation Finance

Re: IGC Pharma, Inc.

Registration Statement on Form S-3 (No. 333-278775)

Ladies and Gentlemen:

IGC Pharma, Inc. hereby requests that the effectiveness of the above-referenced Registration Statement be accelerated so that it will become effective at 4:00 p.m., Eastern time, on Thursday, May 2, 2024, or as soon as possible thereafter.

Very truly yours,
IGC PHARMA, INC.

Show Raw Text

CORRESP
1
filename1.htm

	igcpharma20240430_corresp.htm

April 30, 2024

VIA EMAIL AND EDGAR

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention:         Tim Buchmiller, Esq.

                         Division of Corporation Finance

Re:         IGC Pharma, Inc.

Registration Statement on Form S-3 (No. 333-278775)

Ladies and Gentlemen:

On behalf of IGC Pharma, Inc. (the “Company”), we enclose the Company’s request for acceleration of the above-referenced Registration Statement to 4:00 p.m., Eastern time, on Thursday, May 2, 2024, or as soon as possible thereafter.

Please advise the undersigned of the effectiveness of the Registration Statement.

			Very truly yours,

			/s/ Kenneth Schlesinger

			Kenneth Schlesinger

cc:          Mr. Ram Mukunda

Ms. Claudia Grimaldi

IGC Pharma, Inc.

10224 Falls Road

Potomac, MD 20854

April 30, 2024

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention:         Tim Buchmiller, Esq.

                         Division of Corporation Finance

Re:         IGC Pharma, Inc.

Registration Statement on Form S-3 (No. 333-278775)

Ladies and Gentlemen:

IGC Pharma, Inc. hereby requests that the effectiveness of the above-referenced Registration Statement be accelerated so that it will become effective at 4:00 p.m., Eastern time, on Thursday, May 2, 2024, or as soon as possible thereafter.

			Very truly yours,

			IGC PHARMA, INC.

			By:

			/s/ Ram Mukunda

			Ram Mukunda

			Chief Executive Officer and President

SecProbe.io